Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients | Zendy

Michael Gnant | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients

Author(s) -

Michael Gnant

Publication year - 2010

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000322099

Subject(s) - medicine , zoledronic acid , adjuvant , breast cancer , aromatase , bisphosphonate , oncology , cancer , clinical trial , adjuvant therapy , anastrozole , postmenopausal women , osteoporosis

Adjuvant bisphosphonate therapy is increasingly used in postmenopausal breast cancer patients. This is based on level-one evidence that bisphosphonates, particularly zoledronic acid, can effectively prevent cancer treatment-induced bone loss in breast cancer patients receiving estradiol-lowering endocrine therapies such as aromatase inhibitors. Furthermore, emerging data from large clinical trials suggest that additional anticancer benefits can be derived due to a positive impact on the bone marrow microenvironment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research